hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06317363 id: REC/RCR&AHS/23/0353 briefTitle: Effects of Acapella VS CHEST Physiotherapy in Post-Operative CABG Patients overallStatus: COMPLETED date: 2023-05-23 date: 2024-01-30 date: 2024-02-15 date: 2024-03-19 date: 2024-03-19 name: Riphah International University class: OTHER briefSummary: Coronary artery bypass grafting (CABG) is a surgical procedure that is performed to improve blood flow to the heart by bypassing blocked or narrowed arteries. CABG is a major surgery that is associated with significant postoperative complications, including pulmonary complications such as atelectasis and pneumonia. Chest physiotherapy is commonly use to prevent and treat these complications, but its effectiveness in post-operative CABG patients is not well established.
The purpose of this study is to evaluate the effects of Acapella device vs chest physiotherapy on pulmonary function, airway clearance and dyspnea in post-operative CABG patients. The group A will receive (baseline treatment aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition to using Acapella), while the group B will receive base line treatment. aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition chest physiotherapy percussing for 20 minute The primary outcome measures of the study will be pulmonary function tests, including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and FEV1/FVC, and Modified Borg dyspnea scale . The secondary outcome measures will be the amount of sputum cleared. The study will be conducted over a period of 6 months after approval of synopsis.
The study will be conducted in a tertiary care hospital in Lahore, Pakistan. Patients who have undergone CABG surgery will be screen for eligibility and those who meet the inclusion criteria will be enroll in the study. Patients who have a history of chronic lung disease, smoking, intubated patient or other respiratory conditions will be exclude from the study conditions: CABG studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 30 type: ACTUAL name: Base Line + ACEPELLA name: Base Line + Manual Chest Physiotherapy measure: Modified Borg Dyspnea Scale measure: FEV1 measure: FVC measure: FEV1/FVC measure: sputum volume measure: body temperature(degree centigrade) measure: pulse rate (beats/minute) measure: respiratory rate( breaths/minute) measure: blood pressure (mmHg) measure: SpO2 (%) measure: SaO2 (%) measure: PaO2 (%) measure: PaCO2 (%) sex: ALL minimumAge: 55 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jinnah Hospital city: Lahore state: Punjab zip: 54600 country: Pakistan lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06317350 id: GNS-212-E id: 101772 type: OTHER domain: MFDS briefTitle: Clinical Study to Evaluate the Efficacy and Safety of GNS-212-E in Bowel Preparation for Colonoscopy acronym: GNS-212-E overallStatus: RECRUITING date: 2024-03-11 date: 2025-03-31 date: 2025-03-31 date: 2024-03-19 date: 2024-03-20 name: Gunkang Pharmaceuticals, Inc class: INDUSTRY briefSummary: This is a prospective, randomized, single-blind, parallel, active-controlled, and multi-center Phase III clinical trial. conditions: Colonoscopy conditions: Bowel Preparation studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 318 type: ESTIMATED name: GNS-212-E1 name: GNS-212-E2 name: GNS-212-ER measure: To evaluate the successful % of bowel preparation before colonoscopy (colon cleanliness) using the HCS (Harefield Cleansing Scale) measure: Overall rate of bowel preparation measure: Overall patient satisfaction and compliance sex: ALL minimumAge: 19 Years maximumAge: 79 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Hospital status: RECRUITING city: Seoul country: Korea, Republic of name: Byeong Gwan Kim role: CONTACT lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06317337 id: Sana Bshir briefTitle: Focused Ultrasound Cavitation Augmented With Aerobic Exercise overallStatus: COMPLETED date: 2022-04-15 date: 2023-04-15 date: 2023-07-15 date: 2024-03-19 date: 2024-03-19 name: Riphah International University class: OTHER briefSummary: This study will determine the combine effects of focused ultrasound cavitation augmented with aerobic exercises. This research could be helpful for the patients who prefer such treatments to make a wise decision that either aerobic exercises in combination with cavitation is the better and much safer treatment option to maintain healthy life. conditions: Central Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 54 type: ACTUAL name: focused ultrasound cavitation augmented with aerobic exercises measure: Borg rating of perceived exertion scale measure: girth measure: 6min walk test sex: FEMALE minimumAge: 25 Years maximumAge: 40 Years stdAges: ADULT facility: Bioflex Aesthetic Clinic city: Peshawar state: KPK country: Pakistan lat: 34.008 lon: 71.57849 hasResults: False
nctId: NCT06317324 id: bc2023200 briefTitle: Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invasion. overallStatus: RECRUITING date: 2023-08-01 date: 2024-08-01 date: 2026-08-01 date: 2024-03-19 date: 2024-03-19 name: Tianjin Medical University Cancer Institute and Hospital class: OTHER briefSummary: The goal of this observational study is to compare the prognostic differences between SBRT and Surgery for NSCLC patients with interlobular fissure invasion. The main questions it aims to answer are:
2. Explore of the lung function changes before and after different treatments. conditions: NSCLC conditions: Radiotherapy conditions: Surgery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: Different treatments measure: OS measure: PFS measure: MRFS measure: LRFS measure: VC measure: FVC measure: FEV1 measure: DLCO measure: PFR sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy status: RECRUITING city: Tianjin state: Tianjin zip: 300060 country: China name: Zhao Yan role: CONTACT phone: +86-22-23340123 phoneExt: 5509 email: yanzhaotj@126.com name: Xishan Hao, M.D. role: PRINCIPAL_INVESTIGATOR lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06317298 id: 2023-013-CH01 IIT-RCC briefTitle: Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy overallStatus: RECRUITING date: 2024-02-21 date: 2025-08-01 date: 2025-12-01 date: 2024-03-19 date: 2024-03-19 name: Peking University First Hospital class: OTHER briefSummary: This study will assess the efficacy and safety profile of fruquintinib in combination with everolimus as second line therapy of clear cell renal cell carcinoma patients who progressed after immunotherapy and tyrosine kinase inhibitor. conditions: Renal Cell Carcinoma, Clear Cell, Somatic studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: Fruquintinib and Everolimus measure: MTD (Maximum Tolerated Dose) measure: ORR (Objective Response Rate) measure: PFS (Progression Free Survival) measure: DCR (Decease Control Rate ) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University First Hospital status: RECRUITING city: Beijing country: China name: Zhisong He, MD role: CONTACT phone: +8610-83572418 email: wyj7074@sohu.com name: Kaiwei Yang, MD role: CONTACT phone: 13811501435 email: 13811501435@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06317285 id: 220929 id: 2023-509371-16-00 type: OTHER domain: EU CTR briefTitle: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-03-19 date: 2026-03-19 date: 2024-03-19 date: 2024-03-19 name: GlaxoSmithKline class: INDUSTRY briefSummary: Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants. conditions: Idiopathic Pulmonary Fibrosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: This will be a double-blind study with respect to allocation of GSK3915393 or placebo to participants. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 150 type: ESTIMATED name: GSK3915393 name: Placebo measure: Absolute Change from Baseline in Forced Vital Capacity (FVC) in milliliters (mL) at Week 26 measure: Absolute Change from Baseline in Forced Vital Capacity (mL) at Weeks 4, 8, 12 and 18 measure: Absolute Change from Baseline in Percent Predicted Forced Vital Capacity (%) at Weeks 4, 8, 12, 18 and 26 measure: Participants Achieving Relative Decline from Baseline in FVC (mL) Less than or Equal to (≤) 5 Percent (%) at Week 26 measure: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) measure: Number of Participants with Clinically Important Findings in Vital Signs measure: Number of Participants with Clinically Important Findings in Electrocardiogram (ECG) measure: Number of Participants with Clinically Important Findings in Haematology measure: Number of Participants with Clinically Important Findings in Hepatobiliary Parameters measure: Number of Participants with Clinically Important Findings in Clinical Chemistry measure: Maximum observed concentration (Cmax) of GSK3915393 in IPF Participants measure: Area under the time-concentration curve (AUC) from Zero (pre-dose) to 4 hours (h) post-dose sample [0-4 h]) of GSK3915393 measure: Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC- inf) of GSK3915393 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06317272 id: RT2016-04-BROTHER Part 1 briefTitle: BReath Hold TecHniquEs for Radiotherapy of Esophageal Carcinoma acronym: BROTHER overallStatus: TERMINATED date: 2021-02-10 date: 2023-09-19 date: 2023-09-19 date: 2024-03-19 date: 2024-03-19 name: University Medical Center Groningen class: OTHER briefSummary: The main objective of the first part of the study is to determine the most optimal method for DIBH (active breathing control vs voluntary coached) and its reproducibility. Based on these findings, one of these methods will be selected for part 2 of this study. conditions: Esophageal Cancer studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: The participating patients will undergo weekly (during radiotherapy treatment) 2 CTs in DIBH; one using ABC and one using voluntary coaching (VC). primaryPurpose: TREATMENT masking: NONE count: 1 type: ACTUAL name: DIBH using ABC technique name: DIBH using VC technique measure: Feasibility DIBH measure: Reproducibility DIBH sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UMC Groningen city: Groningen country: Netherlands lat: 53.21917 lon: 6.56667 hasResults: False
nctId: NCT06317259 id: 809163 briefTitle: Effects of Hypoxic Breathwork overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-11 date: 2024-12 date: 2024-03-19 date: 2024-03-20 name: University of California, San Diego class: OTHER briefSummary: This project will study changes that occur during a short period of intensive daily slow-paced breathing and breath hold practice (i.e., "breathwork"). On the first and last days of the week-long practice, investigators will conduct high-density EEG recordings during breathwork to evaluate spectral power, coherence, and causality dynamics of the brain when it is naïve to breathwork and after adaptation to a breathwork practice. Breath, blood, urine, saliva, stool samples, biometric data, and sleep EEG will be collected before the start of daily breathwork practice and again after 1 week of breathwork practice to examine the effect of breathwork on full body biochemistry, molecular biology, and sleep. Investigators will also use questionnaires to assess the impact of breathwork on stress and sleep quality. conditions: Hypoxic Breathwork With Music and Affirmative Messaging conditions: Hypoxic Breathwork Only conditions: Music and Affirmative Messaging studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: We have 3 groups running in parallel (one of each group running in the same week). Group 1 will do breathwork that includes music and positive messaging, group 2 will do breathwork alone with only guided breathing instructions, and group 3 will listen to the music and positive messaging but no breathwork which we call the "meditation" group. primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Subjects will be unaware of the other conditions and will thus not know if they are in a 'control' group or not. All experimenters will know subject group assignments. Subjects will be told of all groups at the end. whoMasked: PARTICIPANT count: 75 type: ESTIMATED name: Hypoxic breathwork plus music and messaging name: Hypoxic breathwork only name: Music and messaging meditation measure: EEG power and/or connectivity differences between groups measure: Group differences in sleep EEG power and/or stage changes from baseline to the intervention period measure: Group differences between physiological changes in proteomics, microbiome, and other factors from baseline following intervention measure: Group differences in mood and stress from before to after the intervention sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT hasResults: False
nctId: NCT06317246 id: ECDSUB briefTitle: Subtypes and Prognostic Factors in Erdheim-Chester Disease overallStatus: RECRUITING date: 2020-09-15 date: 2024-09-15 date: 2024-12-15 date: 2024-03-19 date: 2024-03-19 name: Meyer Children's Hospital IRCCS class: OTHER briefSummary: Erdheim-Chester Disease (ECD) is a rare form of histiocytosis characterized by the proliferation of blood cells, known as histiocytes, which infiltrate various organs and tissues, often causing irreversible damage. The causes of the pathology are still unknown. Although the disease typically affects adult individuals, cases of pediatric-onset ECD have been described. However, there is a lack of detailed information on the phenotypic characteristics of these patients, and reliable data on response to specific therapies and long-term outcomes are missing. Three patients referred to our reference center for Histiocytosis present a concomitant BRAF-mutated neoplasm. Such an association could be due to the presence of mosaicisms for the BRAF V600E mutation. Mosaicism is a biological event defined as the presence of more than one genetically dissimilar cell population in the same organism and is an increasingly studied field, both in normal and pathological conditions. If proven in ECD as well, this mechanism could contribute to providing answers to the still open questions regarding the development of this disease. conditions: Erdheim-Chester Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 70 type: ESTIMATED name: Investigation of BRAF mosaicism measure: Clinical characteristics of patients with Erdheim-Chester Disease measure: Prognostic factors of patients with Erdheim-Chester Disease sex: ALL minimumAge: 1 Year maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Meyer Children's Hospital IRCCS status: RECRUITING city: Florence state: Firenze country: Italy name: Augusto Vaglio role: CONTACT email: augusto.vaglio@meyer.it lat: 43.77925 lon: 11.24626 facility: AOU Parma status: RECRUITING city: Parma country: Italy name: Domenico Corradi role: CONTACT email: domenico.corradi@unipr.it lat: 44.79935 lon: 10.32618 hasResults: False
nctId: NCT06317233 id: STUDY00007131 briefTitle: Outcomes of a Multidisciplinary Program for the Treatment of Chronic Pelvic Pain overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-09 date: 2024-10 date: 2024-03-19 date: 2024-03-19 name: Medstar Health Research Institute class: OTHER briefSummary: The goal of this clinical trial is to test the impact of a detailed treatment handbook and follow-up schedule on women seeking care for chronic pelvic pain in a gynecology office-based practice. The main questions it aims to answer are:
* How does the handbook and follow-up impact patient pain and quality of life scores? Participants will be randomized to receive the office standard of care, or standard of care plus a printed handbook customized to highlight their diagnosis, treatment plan and follow-up schedule. conditions: Chronic Pelvic Pain Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Chronic Pelvic Pain Treatment Guide measure: Patient Satisfaction measure: Pain Catastrophizing measure: Pelvic Pain sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-01-29 uploadDate: 2024-03-03T20:29 filename: Prot_000.pdf size: 138543 hasResults: False
nctId: NCT06317220 id: 2024P000152 briefTitle: Vedolizumab for the Treatment of Collagenous Gastritis overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-06-01 date: 2028-04-01 date: 2024-03-19 date: 2024-03-19 name: Massachusetts General Hospital class: OTHER name: Takeda name: Dana-Farber Cancer Institute briefSummary: The goal of this clinical trial is to learn about how vedolizumab may affect patients with collagenous gastritis (CG). The main questions it aims to answer are:
* Undergo an endoscopy with biopsy conditions: Collagenous Gastritis studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Vedolizumab measure: Change in symtpoms measure: Response durability measure: Histologic response measure: Incidence of treatment-emergent adverse events (safety) measure: Immunologic response in gastric mucosa measure: Immunologic response in peripheral blood sex: ALL minimumAge: 14 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Massachusetts General Hospital city: Boston state: Massachusetts zip: 02114 country: United States name: Keri Sullivan role: CONTACT phone: 617-724-0195 email: ksullivan79@mgh.harvard.edu name: Jamie DiCarlo role: CONTACT phone: 617-724-9347 email: jdicarlo3@mgh.harvard.edu name: Michael L Dougan, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Lestat Ali, MD role: SUB_INVESTIGATOR lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06317207 id: PJ2024-01-44 id: 2019b07030004 type: OTHER_GRANT domain: Anhui Provincial Central Government Guides Local Science and Technology Development Project-Anhui Clinical Research Ce briefTitle: Evaluation of the Safety of Reoperation for Ipsilateral Recurrent Tumors After Nephron-sparing Partial Nephrectomy acronym: LiangAH overallStatus: COMPLETED date: 2013-01-01 date: 2023-12-31 date: 2023-12-31 date: 2024-03-19 date: 2024-03-19 name: The First Affiliated Hospital of Anhui Medical University class: OTHER briefSummary: To evaluate the safety of reoperation in patients with renal tumors who have ipsilateral tumor recurrence after nephron-sparing partial nephrectomy. conditions: Renal Cell Carcinoma conditions: Robotic Surgical Procedures studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 15 type: ACTUAL measure: Operation time measure: Estimated blood loss sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06317194 id: Magnetic Tides briefTitle: A Novel Method of Non-Invasive Brain Stimulation (kTMP) to Enhance Motor Function in Chronic Stroke Patients overallStatus: ENROLLING_BY_INVITATION date: 2024-03-15 date: 2027-06-30 date: 2027-08-30 date: 2024-03-19 date: 2024-03-19 name: Magnetic Tides class: INDUSTRY name: University of California, Berkeley briefSummary: Stroke is a leading cause of disability with many patients suffering chronic motor function impairments that affect their day-to-day activities. The goal of this proposal is to provide a first assessment of the efficacy of an innovative non-invasive brain stimulation system, kTMP, in the treatment of motor impairment following stroke. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 15 type: ESTIMATED name: kTMP name: Sham kTMP measure: Fugl- Meyer Assessment (Upper Extremity) measure: Action Research Arm Test (ARAT) measure: Modified Ashworth Scale (MAS) measure: Trial to Trial Variability (T2TV) measure: Range of Joint Motion (ROM) measure: Grasp to Lift Time measure: Transport Time sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Magnetic Tides city: El Cerrito state: California zip: 94530 country: United States lat: 37.91576 lon: -122.31164 hasResults: False
nctId: NCT06317181 id: DifLivSPECTRUS briefTitle: Assessment of Liver Diseases Using a Deep-Learning Approach Based on Ultrasound RF-Data acronym: LivSPECTRUS overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-06 date: 2025-12 date: 2024-03-19 date: 2024-03-19 name: Technische Universität Dresden class: OTHER name: University Hospital Dresden name: University of Leipzig briefSummary: The goal of this clinical trial is to test the performance of neuronal networks trained on ultrasonic raw Data (=radiofrequency data) for the assessment of liver diseases in patients undergoing a clinical ultrasound examination. The general feasibility is currently evaluated in a retrospective cohort.
* a clinical ultrasound examination during which b-mode images and the corresponding RF-Data sets are captured conditions: Artificial Intelligence conditions: Ultrasonography conditions: Elasticity Imaging Techniques conditions: Liver Diseases conditions: Metastasis to Liver studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Data is collected in a defined group of patients (all patients listed for elastography or for ultrasonic investigation due to a focal lesion in participating departments). Afterwards performances of algorithms are compared based on this group. primaryPurpose: DIAGNOSTIC masking: NONE count: 200 type: ESTIMATED name: Collection of elastography data name: Collection of ultrasonic raw data measure: Performance analysis of the trained model sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-03-01 uploadDate: 2024-03-15T03:02 filename: Prot_000.pdf size: 271228 hasResults: False